Blood pressure control in type 2 diabetes mellitus.

Blood pressure control in type 2 diabetes mellitus.
复制标题

DOI:
10.1053/j.ajkd.2010.08.007
复制
发表时间:
2010-12
期刊:
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子:
--
通讯作者:
Chertow GM
Chertow GM
中科院分区:
其他
文献类型:
--
作者:
Chang TI;Cheung AK;Chertow GM

文献摘要

参考文献

相似文献

糖尿病是发达国家最重要的疾病之一,影响美国2360万成年人和全世界超过1.71亿成年人,1其中大多数患有2型糖尿病。心血管疾病是糖尿病患者死亡的主要原因。2由于75%的糖尿病患者患有全身性高血压,这也是一个主要的心血管风险因素,因此在这一人群中高度关注血压(BP)控制至关重要。2型糖尿病患者使用抗高血压药物治疗降低了心血管事件和死亡的风险,3-5和国家高血压预防、检测、评估和治疗联合委员会第七次报告(JNC 7)建议将糖尿病患者的血压目标定为< 130/80 mm Hg。6然而,支持130/80 mm Hg目标的证据很少。在2型糖尿病和高血压患者的少数随机试验中,3,4,7没有先前的试验达到平均血压< 130/80 mm Hg,试验结论好坏参半。
Diabetes mellitus is among the developed world’s most important diseases, affecting 23.6 million adults in the United States and more than 171 million adults worldwide, 1 most of whom have type 2 diabetes. Cardiovascular disease is the leading cause of death in persons with diabetes mellitus. 2 Because 75% of persons with diabetes mellitus have systemic hypertension, which is also a major cardiovascular risk factor, a high level of attention to blood pressure (BP) control in this population is essential. Treatment with antihypertensive agents in persons with type 2 diabetes has decreased the risk of cardiovascular events and death, 3–5 and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends targeting BPs to< 130/80 mm Hg in persons with diabetes. 6 However, evidence supporting the 130/80 mm Hg target is scant. Of the handful of randomized trials in patients with type 2 diabetes and hypertension, 3, 4, 7 no prior trial has achieved average BPs< 130/80 mm Hg, and trial conclusions have been mixed.
DOI: 10.1016/s0140-6736(98)04311-6
发表时间: 1998-06-13
期刊: LANCET
影响因子: 168.9
作者:
Hansson, L;Zanchetti, A;Westerling, S
通讯作者: Westerling, S
DOI: 10.1056/nejmoa1001282
发表时间: 2010-04-29
期刊: The New England journal of medicine
影响因子: --
作者:
ACCORD Study Group;Ginsberg HN;Elam MB;Lovato LC;Crouse JR 3rd;Leiter LA;Linz P;Friedewald WT;Buse JB;Gerstein HC;Probstfield J;Grimm RH;Ismail-Beigi F;Bigger JT;Goff DC Jr;Cushman WC;Simons-Morton DG;Byington RP
通讯作者: Byington RP
DOI: 10.1056/nejm199803053381003
发表时间: 1998-03-05
影响因子: 158.5
作者:
Estacio, RO;Jeffers, BW;Schrier, RW
通讯作者: Schrier, RW
DOI: 10.1016/s0140-6736(07)61303-8
发表时间: 2007-09-08
期刊: LANCET
影响因子: 168.9
作者:
Patel, A.;MacMahon, S.;Williams, B.
通讯作者: Williams, B.
DOI: 10.1056/nejmoa1001286
发表时间: 2010-04-29
期刊: The New England journal of medicine
影响因子: --
作者:
ACCORD Study Group;Cushman WC;Evans GW;Byington RP;Goff DC Jr;Grimm RH Jr;Cutler JA;Simons-Morton DG;Basile JN;Corson MA;Probstfield JL;Katz L;Peterson KA;Friedewald WT;Buse JB;Bigger JT;Gerstein HC;Ismail-Beigi F
通讯作者: Ismail-Beigi F